{"id":"metformin-janufer-janumet","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":"5–10","effect":"Headache"},{"rate":"5–15","effect":"Hypoglycemia (when combined with other agents)"},{"rate":"5–10","effect":"Nasopharyngitis"},{"rate":"<0.1","effect":"Lactic acidosis (rare, metformin-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Janumet combines two complementary antidiabetic agents with different mechanisms. Metformin acts primarily on the liver to decrease glucose output and enhance peripheral insulin sensitivity. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of endogenous GLP-1 and GIP, thereby stimulating glucose-dependent insulin secretion and suppressing glucagon secretion in a glucose-dependent manner.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while sitagliptin (Januvia) inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:58.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT00684528","phase":"PHASE3","title":"A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2008-06","conditions":"Diabetes Type 2","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metformin + Janufer (Janumet)","genericName":"Metformin + Janufer (Janumet)","companyName":"Meir Medical Center","companyId":"meir-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while sitagliptin (Januvia) inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}